Ratings by Goldman Sachs (Matt Dellatorre)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/9/2026 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 9/23/2025 | Teva Pharma | TEVA | Maintain | Buy (N/A) |
|
Details | ||
| 7/18/2025 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 6/30/2025 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 6/6/2025 | Viatris | VTRS | New Coverage | Neutral (Neutral) |
8.59 (16.70) |
94.41% | Details | |
| 6/6/2025 | Amneal Pharmaceuticals | AMRX | New Coverage | Neutral (N/A) |
7.21 (17.15) |
137.86% | Details | |
| 6/6/2025 | Teva Pharma | TEVA | New Coverage | Buy (N/A) |
17.52 (34.64) |
97.72% | Details |
